Stock movement looks familiar.
Will the pattern hold?
Also, Botox rival, Revance Therapeutics, got approved. Longer lasting than Botox. Remains to be seen if it can eat into ABBV's market share.
Also, Botox rival, Revance Therapeutics, got approved. Longer lasting than Botox. Remains to be seen if it can eat into ABBV's market share.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.